Eureka Genomics (EG) develops Next Generation Sequencing (NGS)-based assays and diagnostics. The EG technology platform uses proprietary software, algorithms and database to build bioinformatics applications and services, focusing NGS assay design and translating data into useful, comprehensive and powerful analysis of NGS data. As a leader in advanced bioinformatics analysis of NGS data, EG leverages this expertise building the backbone of their novel next-gen genotyping (NGG). The NGG for clinical, animal and crop applications enable highly-efficient, targeted sequencing and flexible exploration of relevant genetic markers (SNPs, CNV, gene expression, methylation) in a massively parallel, platform agnostic technology. In addition, the company is currently developing molecular diagnostics for the identification of colorectal cancer and pre-term birth and exploring other opportunities for diagnostic development.